Catalyst Pharmaceuticals to be Acquired by Angelini Pharma for $4.1 Billion; Resolves Key Patent Litigation

summarizeSummary

Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per share in cash, totaling approximately $4.1 billion. This announcement also includes the resolution of FIRDAPSE patent litigation, securing market exclusivity until January 2035.

check_boxKey Events

• Definitive Merger Agreement

  Catalyst Pharmaceuticals will be acquired by Angelini Pharma for $31.50 per share in cash, valuing the company at approximately $4.1 billion.

• Significant Acquisition Premium

  The offer price represents a 21% premium to Catalyst's unaffected closing share price on April 22, 2026, and a 28% premium to the 30-day volume-weighted average trading price.

• FIRDAPSE Patent Litigation Resolved

  All pending patent litigation for FIRDAPSE has been resolved, preventing generic entry until January 2035 and securing a key revenue stream.

• Shareholder & Regulatory Approvals

  The merger is subject to Catalyst stockholder approval and customary regulatory clearances, with closing anticipated in Q3 2026.

auto_awesomeAnalysis

This filing confirms the definitive agreement for Angelini Pharma to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at approximately $4.1 billion. This represents a substantial premium to Catalyst's recent trading prices and market capitalization, offering immediate and certain cash value to shareholders. The simultaneous announcement of the FIRDAPSE patent litigation settlement, which prevents generic entry until January 2035, significantly de-risks Catalyst's key revenue stream and enhances the value proposition for the acquirer. This dual development provides a strong positive signal, solidifying the company's future and removing significant uncertainties. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.